Global Meningococcal Vaccine Supply, Demand and Key Producers, 2026-2032
The global Meningococcal Vaccine market size is expected to reach $ 6544 million by 2032, rising at a market growth of 6.2% CAGR during the forecast period (2026-2032).
Meningococcal vaccines are preventive biological products designed to generate active immunity against invasive disease caused by Neisseria meningitidis. They are used in routine childhood and adolescent immunization, preventive campaigns, outbreak response, travel vaccination and the protection of medically or occupationally exposed populations. Current marketed serogroup configurations include monovalent MenA, MenB and MenC vaccines; bivalent MenAC and MenBC vaccines; trivalent MenACW vaccines; quadrivalent MenACWY vaccines; and pentavalent MenABCWY and MenACWYX vaccines. MenABCWY is an emerging commercial segment represented by Pfizer?s Penbraya and GSK?s Penmenvy, while MenACWYX is represented by Serum Institute of India?s MenFive. Commercial technology platforms comprise plain polysaccharide vaccines, conjugate vaccines, recombinant protein vaccines and multi-platform products combining conjugate, recombinant protein or outer-membrane-vesicle components.
Upstream supply depends on qualified meningococcal strains, capsular polysaccharides, recombinant antigens, outer-membrane-vesicle antigens, carrier proteins, stabilizers, sterile containers and validated cold-chain packaging. Manufacturing remains concentrated because biological consistency, aseptic processing, analytical comparability, regulatory approval and lot-release testing must be maintained over long production cycles. Downstream purchasers include ministries of health, national immunization programs, international procurement organizations, hospitals, vaccination clinics, pharmacies, travel-health centers, military organizations, universities and occupational-health providers. Public demand is commonly supplied through annual tenders, multi-year framework agreements, stockpile contracts and emergency procurement, while commercial vaccines are distributed through direct supply agreements and specialist health-care channels. Industry gross margin is estimated at approximately 68%, supported by premium-priced conjugate, MenB and pentavalent products but moderated by lower-price public-health procurement.
In the current market, global production of meningococcal vaccines is around 197 million doses, with an average selling price of about 21.00 USD per dose on an EXW basis. Value is more concentrated than physical volume because commercial MenB, MenACWY and MenABCWY vaccines command substantially higher prices than polysaccharide and public-procurement products used extensively in China and the African meningitis belt. The top five suppliers control approximately 84% of global revenue. GSK leads through Bexsero, Menveo and Penmenvy, followed by Sanofi and Pfizer. Serum Institute of India has an important position in African public-health procurement through MenAfriVac and MenFive, although its revenue share is lower than its dose share. China has a broader manufacturing base spanning MenA, MenAC and MenACWY products. North America is the largest value market, followed by Europe, while China and Africa account for a disproportionately large share of global dose volume.
During 2026?2032, demand is expected to move further from plain polysaccharide vaccines toward conjugate and broader multivalent products. MenFive adoption should expand protection against serogroups A, C, W, Y and X in the African meningitis belt. MenABCWY products may simplify immunization for adolescents and high-risk populations currently requiring separate MenACWY and MenB vaccinations. However, the pentavalent category will remain concentrated in a small number of manufacturers because of its complex antigen composition, clinical requirements and multi-component presentation. Regulatory authorities will continue to emphasize lot consistency, age-specific effectiveness, post-marketing surveillance and long-term supply reliability. Public tenders will maintain pricing pressure, while wider reimbursement of MenB and pentavalent vaccines should support gradual ASP growth. Key bottlenecks include long biological production and release cycles, limited antigen and carrier-protein capacity, sterile fill-finish constraints, cold-chain requirements and irregular government procurement. Changes in circulating serogroups may also require revisions to national schedules and stockpile composition.
This report studies the global Meningococcal Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Meningococcal Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Meningococcal Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Meningococcal Vaccine total production and demand, 2021-2032, (million Dose)
Global Meningococcal Vaccine total production value, 2021-2032, (USD Million)
Global Meningococcal Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (million Dose), (based on production site)
Global Meningococcal Vaccine consumption by region & country, CAGR, 2021-2032 & (million Dose)
U.S. VS China: Meningococcal Vaccine domestic production, consumption, key domestic manufacturers and share
Global Meningococcal Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (million Dose)
Global Meningococcal Vaccine production by Vaccine Platform, production, value, CAGR, 2021-2032, (USD Million) & (million Dose)
Global Meningococcal Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (million Dose)
This report profiles key players in the global Meningococcal Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Sanofi, Pfizer, Serum Institute of India, CanSino Biologics, Yuxi Walvax Biotechnology, Beijing Zhifei Lvzhu Biopharmaceutical, China National Biotec Group, Funda??o Oswaldo Cruz, Funda??o Ezequiel Dias, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Meningococcal Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (million Dose) and average price (US$/Dose) by manufacturer, by Vaccine Platform, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Meningococcal Vaccine Market, By Region:
1. How big is the global Meningococcal Vaccine market?
2. What is the demand of the global Meningococcal Vaccine market?
3. What is the year over year growth of the global Meningococcal Vaccine market?
4. What is the production and production value of the global Meningococcal Vaccine market?
5. Who are the key producers in the global Meningococcal Vaccine market?
6. What are the growth factors driving the market demand?
Meningococcal vaccines are preventive biological products designed to generate active immunity against invasive disease caused by Neisseria meningitidis. They are used in routine childhood and adolescent immunization, preventive campaigns, outbreak response, travel vaccination and the protection of medically or occupationally exposed populations. Current marketed serogroup configurations include monovalent MenA, MenB and MenC vaccines; bivalent MenAC and MenBC vaccines; trivalent MenACW vaccines; quadrivalent MenACWY vaccines; and pentavalent MenABCWY and MenACWYX vaccines. MenABCWY is an emerging commercial segment represented by Pfizer?s Penbraya and GSK?s Penmenvy, while MenACWYX is represented by Serum Institute of India?s MenFive. Commercial technology platforms comprise plain polysaccharide vaccines, conjugate vaccines, recombinant protein vaccines and multi-platform products combining conjugate, recombinant protein or outer-membrane-vesicle components.
Upstream supply depends on qualified meningococcal strains, capsular polysaccharides, recombinant antigens, outer-membrane-vesicle antigens, carrier proteins, stabilizers, sterile containers and validated cold-chain packaging. Manufacturing remains concentrated because biological consistency, aseptic processing, analytical comparability, regulatory approval and lot-release testing must be maintained over long production cycles. Downstream purchasers include ministries of health, national immunization programs, international procurement organizations, hospitals, vaccination clinics, pharmacies, travel-health centers, military organizations, universities and occupational-health providers. Public demand is commonly supplied through annual tenders, multi-year framework agreements, stockpile contracts and emergency procurement, while commercial vaccines are distributed through direct supply agreements and specialist health-care channels. Industry gross margin is estimated at approximately 68%, supported by premium-priced conjugate, MenB and pentavalent products but moderated by lower-price public-health procurement.
In the current market, global production of meningococcal vaccines is around 197 million doses, with an average selling price of about 21.00 USD per dose on an EXW basis. Value is more concentrated than physical volume because commercial MenB, MenACWY and MenABCWY vaccines command substantially higher prices than polysaccharide and public-procurement products used extensively in China and the African meningitis belt. The top five suppliers control approximately 84% of global revenue. GSK leads through Bexsero, Menveo and Penmenvy, followed by Sanofi and Pfizer. Serum Institute of India has an important position in African public-health procurement through MenAfriVac and MenFive, although its revenue share is lower than its dose share. China has a broader manufacturing base spanning MenA, MenAC and MenACWY products. North America is the largest value market, followed by Europe, while China and Africa account for a disproportionately large share of global dose volume.
During 2026?2032, demand is expected to move further from plain polysaccharide vaccines toward conjugate and broader multivalent products. MenFive adoption should expand protection against serogroups A, C, W, Y and X in the African meningitis belt. MenABCWY products may simplify immunization for adolescents and high-risk populations currently requiring separate MenACWY and MenB vaccinations. However, the pentavalent category will remain concentrated in a small number of manufacturers because of its complex antigen composition, clinical requirements and multi-component presentation. Regulatory authorities will continue to emphasize lot consistency, age-specific effectiveness, post-marketing surveillance and long-term supply reliability. Public tenders will maintain pricing pressure, while wider reimbursement of MenB and pentavalent vaccines should support gradual ASP growth. Key bottlenecks include long biological production and release cycles, limited antigen and carrier-protein capacity, sterile fill-finish constraints, cold-chain requirements and irregular government procurement. Changes in circulating serogroups may also require revisions to national schedules and stockpile composition.
This report studies the global Meningococcal Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Meningococcal Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Meningococcal Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Meningococcal Vaccine total production and demand, 2021-2032, (million Dose)
Global Meningococcal Vaccine total production value, 2021-2032, (USD Million)
Global Meningococcal Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (million Dose), (based on production site)
Global Meningococcal Vaccine consumption by region & country, CAGR, 2021-2032 & (million Dose)
U.S. VS China: Meningococcal Vaccine domestic production, consumption, key domestic manufacturers and share
Global Meningococcal Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (million Dose)
Global Meningococcal Vaccine production by Vaccine Platform, production, value, CAGR, 2021-2032, (USD Million) & (million Dose)
Global Meningococcal Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (million Dose)
This report profiles key players in the global Meningococcal Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Sanofi, Pfizer, Serum Institute of India, CanSino Biologics, Yuxi Walvax Biotechnology, Beijing Zhifei Lvzhu Biopharmaceutical, China National Biotec Group, Funda??o Oswaldo Cruz, Funda??o Ezequiel Dias, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Meningococcal Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (million Dose) and average price (US$/Dose) by manufacturer, by Vaccine Platform, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Meningococcal Vaccine Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Plain Polysaccharide Vaccines
- Conjugate Vaccines
- Recombinant Protein Vaccines
- Multi-Platform Vaccines
- MenA Vaccines
- MenB Vaccines
- MenC Vaccines
- MenAC Vaccines
- MenBC Vaccines
- MenACW Vaccines
- MenACWY Vaccines
- MenABCWY Vaccines
- MenACWYX Vaccines
- Single-Dose Liquid
- Multi-Dose Liquid
- Single-Dose Lyophilized
- Multi-Dose Lyophilized
- Multi-Component Kit
- Routine Pediatric Immunization
- Routine Adolescent Immunization
- Preventive Mass Campaigns
- Outbreak Response
- High-Risk Clinical Immunization
- Travel Immunization
- Institutional Immunization
- Occupational Immunization
- Catch-Up Immunization
- Other Immunization
- GSK
- Sanofi
- Pfizer
- Serum Institute of India
- CanSino Biologics
- Yuxi Walvax Biotechnology
- Beijing Zhifei Lvzhu Biopharmaceutical
- China National Biotec Group
- Funda??o Oswaldo Cruz
- Funda??o Ezequiel Dias
- Instituto Finlay de Vacunas
- PT Bio Farma
- Hualan Biological Bacterin
- Chengdu Olymvax Biopharmaceuticals
- Royal Wuxi Bio-Pharmaceutical
- AIM Persistence Biopharmaceutical
- NPO Microgen
- Incepta Vaccine
1. How big is the global Meningococcal Vaccine market?
2. What is the demand of the global Meningococcal Vaccine market?
3. What is the year over year growth of the global Meningococcal Vaccine market?
4. What is the production and production value of the global Meningococcal Vaccine market?
5. Who are the key producers in the global Meningococcal Vaccine market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Meningococcal Vaccine Introduction
1.2 World Meningococcal Vaccine Supply & Forecast
1.2.1 World Meningococcal Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Meningococcal Vaccine Production (2021-2032)
1.2.3 World Meningococcal Vaccine Pricing Trends (2021-2032)
1.3 World Meningococcal Vaccine Production by Region (Based on Production Site)
1.3.1 World Meningococcal Vaccine Production Value by Region (2021-2032)
1.3.2 World Meningococcal Vaccine Production by Region (2021-2032)
1.3.3 World Meningococcal Vaccine Average Price by Region (2021-2032)
1.3.4 North America Meningococcal Vaccine Production (2021-2032)
1.3.5 Europe Meningococcal Vaccine Production (2021-2032)
1.3.6 China Meningococcal Vaccine Production (2021-2032)
1.3.7 India Meningococcal Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Meningococcal Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Meningococcal Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Meningococcal Vaccine Demand (2021-2032)
2.2 World Meningococcal Vaccine Consumption by Region
2.2.1 World Meningococcal Vaccine Consumption by Region (2021-2026)
2.2.2 World Meningococcal Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Meningococcal Vaccine Consumption (2021-2032)
2.4 China Meningococcal Vaccine Consumption (2021-2032)
2.5 Europe Meningococcal Vaccine Consumption (2021-2032)
2.6 Japan Meningococcal Vaccine Consumption (2021-2032)
2.7 South Korea Meningococcal Vaccine Consumption (2021-2032)
2.8 ASEAN Meningococcal Vaccine Consumption (2021-2032)
2.9 India Meningococcal Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Meningococcal Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Meningococcal Vaccine Production by Manufacturer (2021-2026)
3.3 World Meningococcal Vaccine Average Price by Manufacturer (2021-2026)
3.4 Meningococcal Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Meningococcal Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Meningococcal Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Meningococcal Vaccine in 2025
3.6 Meningococcal Vaccine Market: Overall Company Footprint Analysis
3.6.1 Meningococcal Vaccine Market: Region Footprint
3.6.2 Meningococcal Vaccine Market: Company Product Type Footprint
3.6.3 Meningococcal Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Meningococcal Vaccine Production Value Comparison
4.1.1 United States VS China: Meningococcal Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Meningococcal Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Meningococcal Vaccine Production Comparison
4.2.1 United States VS China: Meningococcal Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Meningococcal Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Meningococcal Vaccine Consumption Comparison
4.3.1 United States VS China: Meningococcal Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Meningococcal Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Meningococcal Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Meningococcal Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Meningococcal Vaccine Production (2021-2026)
4.5 China Based Meningococcal Vaccine Manufacturers and Market Share
4.5.1 China Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Meningococcal Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Meningococcal Vaccine Production (2021-2026)
4.6 Rest of World Based Meningococcal Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Meningococcal Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Meningococcal Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY VACCINE PLATFORM
5.1 World Meningococcal Vaccine Market Size Overview by Vaccine Platform: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Vaccine Platform
5.2.1 Plain Polysaccharide Vaccines
5.2.2 Conjugate Vaccines
5.2.3 Recombinant Protein Vaccines
5.2.4 Multi-Platform Vaccines
5.3 Market Segment by Vaccine Platform
5.3.1 World Meningococcal Vaccine Production by Vaccine Platform (2021-2032)
5.3.2 World Meningococcal Vaccine Production Value by Vaccine Platform (2021-2032)
5.3.3 World Meningococcal Vaccine Average Price by Vaccine Platform (2021-2032)
6 MARKET ANALYSIS BY SEROGROUP COVERAGE
6.1 World Meningococcal Vaccine Market Size Overview by Serogroup Coverage: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Serogroup Coverage
6.2.1 MenA Vaccines
6.2.2 MenB Vaccines
6.2.3 MenC Vaccines
6.2.4 MenAC Vaccines
6.2.5 MenBC Vaccines
6.2.6 MenACW Vaccines
6.2.7 MenACWY Vaccines
6.2.8 MenABCWY Vaccines
6.2.9 MenACWYX Vaccines
6.3 Market Segment by Serogroup Coverage
6.3.1 World Meningococcal Vaccine Production by Serogroup Coverage (2021-2032)
6.3.2 World Meningococcal Vaccine Production Value by Serogroup Coverage (2021-2032)
6.3.3 World Meningococcal Vaccine Average Price by Serogroup Coverage (2021-2032)
7 MARKET ANALYSIS BY PRESENTATION
7.1 World Meningococcal Vaccine Market Size Overview by Presentation: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Presentation
7.2.1 Single-Dose Liquid
7.2.2 Multi-Dose Liquid
7.2.3 Single-Dose Lyophilized
7.2.4 Multi-Dose Lyophilized
7.2.5 Multi-Component Kit
7.3 Market Segment by Presentation
7.3.1 World Meningococcal Vaccine Production by Presentation (2021-2032)
7.3.2 World Meningococcal Vaccine Production Value by Presentation (2021-2032)
7.3.3 World Meningococcal Vaccine Average Price by Presentation (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Meningococcal Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Routine Pediatric Immunization
8.2.2 Routine Adolescent Immunization
8.2.3 Preventive Mass Campaigns
8.2.4 Outbreak Response
8.2.5 High-Risk Clinical Immunization
8.2.6 Travel Immunization
8.2.7 Institutional Immunization
8.2.8 Occupational Immunization
8.2.9 Catch-Up Immunization
8.3 Market Segment by Application
8.3.1 World Meningococcal Vaccine Production by Application (2021-2032)
8.3.2 World Meningococcal Vaccine Production Value by Application (2021-2032)
8.3.3 World Meningococcal Vaccine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 GSK
9.1.1 GSK Details
9.1.2 GSK Major Business
9.1.3 GSK Meningococcal Vaccine Product and Services
9.1.4 GSK Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 GSK Recent Developments/Updates
9.1.6 GSK Competitive Strengths & Weaknesses
9.2 Sanofi
9.2.1 Sanofi Details
9.2.2 Sanofi Major Business
9.2.3 Sanofi Meningococcal Vaccine Product and Services
9.2.4 Sanofi Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Sanofi Recent Developments/Updates
9.2.6 Sanofi Competitive Strengths & Weaknesses
9.3 Pfizer
9.3.1 Pfizer Details
9.3.2 Pfizer Major Business
9.3.3 Pfizer Meningococcal Vaccine Product and Services
9.3.4 Pfizer Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Pfizer Recent Developments/Updates
9.3.6 Pfizer Competitive Strengths & Weaknesses
9.4 Serum Institute of India
9.4.1 Serum Institute of India Details
9.4.2 Serum Institute of India Major Business
9.4.3 Serum Institute of India Meningococcal Vaccine Product and Services
9.4.4 Serum Institute of India Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Serum Institute of India Recent Developments/Updates
9.4.6 Serum Institute of India Competitive Strengths & Weaknesses
9.5 CanSino Biologics
9.5.1 CanSino Biologics Details
9.5.2 CanSino Biologics Major Business
9.5.3 CanSino Biologics Meningococcal Vaccine Product and Services
9.5.4 CanSino Biologics Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 CanSino Biologics Recent Developments/Updates
9.5.6 CanSino Biologics Competitive Strengths & Weaknesses
9.6 Yuxi Walvax Biotechnology
9.6.1 Yuxi Walvax Biotechnology Details
9.6.2 Yuxi Walvax Biotechnology Major Business
9.6.3 Yuxi Walvax Biotechnology Meningococcal Vaccine Product and Services
9.6.4 Yuxi Walvax Biotechnology Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Yuxi Walvax Biotechnology Recent Developments/Updates
9.6.6 Yuxi Walvax Biotechnology Competitive Strengths & Weaknesses
9.7 Beijing Zhifei Lvzhu Biopharmaceutical
9.7.1 Beijing Zhifei Lvzhu Biopharmaceutical Details
9.7.2 Beijing Zhifei Lvzhu Biopharmaceutical Major Business
9.7.3 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product and Services
9.7.4 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Beijing Zhifei Lvzhu Biopharmaceutical Recent Developments/Updates
9.7.6 Beijing Zhifei Lvzhu Biopharmaceutical Competitive Strengths & Weaknesses
9.8 China National Biotec Group
9.8.1 China National Biotec Group Details
9.8.2 China National Biotec Group Major Business
9.8.3 China National Biotec Group Meningococcal Vaccine Product and Services
9.8.4 China National Biotec Group Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 China National Biotec Group Recent Developments/Updates
9.8.6 China National Biotec Group Competitive Strengths & Weaknesses
9.9 Funda??o Oswaldo Cruz
9.9.1 Funda??o Oswaldo Cruz Details
9.9.2 Funda??o Oswaldo Cruz Major Business
9.9.3 Funda??o Oswaldo Cruz Meningococcal Vaccine Product and Services
9.9.4 Funda??o Oswaldo Cruz Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Funda??o Oswaldo Cruz Recent Developments/Updates
9.9.6 Funda??o Oswaldo Cruz Competitive Strengths & Weaknesses
9.10 Funda??o Ezequiel Dias
9.10.1 Funda??o Ezequiel Dias Details
9.10.2 Funda??o Ezequiel Dias Major Business
9.10.3 Funda??o Ezequiel Dias Meningococcal Vaccine Product and Services
9.10.4 Funda??o Ezequiel Dias Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Funda??o Ezequiel Dias Recent Developments/Updates
9.10.6 Funda??o Ezequiel Dias Competitive Strengths & Weaknesses
9.11 Instituto Finlay de Vacunas
9.11.1 Instituto Finlay de Vacunas Details
9.11.2 Instituto Finlay de Vacunas Major Business
9.11.3 Instituto Finlay de Vacunas Meningococcal Vaccine Product and Services
9.11.4 Instituto Finlay de Vacunas Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Instituto Finlay de Vacunas Recent Developments/Updates
9.11.6 Instituto Finlay de Vacunas Competitive Strengths & Weaknesses
9.12 PT Bio Farma
9.12.1 PT Bio Farma Details
9.12.2 PT Bio Farma Major Business
9.12.3 PT Bio Farma Meningococcal Vaccine Product and Services
9.12.4 PT Bio Farma Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 PT Bio Farma Recent Developments/Updates
9.12.6 PT Bio Farma Competitive Strengths & Weaknesses
9.13 Hualan Biological Bacterin
9.13.1 Hualan Biological Bacterin Details
9.13.2 Hualan Biological Bacterin Major Business
9.13.3 Hualan Biological Bacterin Meningococcal Vaccine Product and Services
9.13.4 Hualan Biological Bacterin Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Hualan Biological Bacterin Recent Developments/Updates
9.13.6 Hualan Biological Bacterin Competitive Strengths & Weaknesses
9.14 Chengdu Olymvax Biopharmaceuticals
9.14.1 Chengdu Olymvax Biopharmaceuticals Details
9.14.2 Chengdu Olymvax Biopharmaceuticals Major Business
9.14.3 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product and Services
9.14.4 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Chengdu Olymvax Biopharmaceuticals Recent Developments/Updates
9.14.6 Chengdu Olymvax Biopharmaceuticals Competitive Strengths & Weaknesses
9.15 Royal Wuxi Bio-Pharmaceutical
9.15.1 Royal Wuxi Bio-Pharmaceutical Details
9.15.2 Royal Wuxi Bio-Pharmaceutical Major Business
9.15.3 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product and Services
9.15.4 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Royal Wuxi Bio-Pharmaceutical Recent Developments/Updates
9.15.6 Royal Wuxi Bio-Pharmaceutical Competitive Strengths & Weaknesses
9.16 AIM Persistence Biopharmaceutical
9.16.1 AIM Persistence Biopharmaceutical Details
9.16.2 AIM Persistence Biopharmaceutical Major Business
9.16.3 AIM Persistence Biopharmaceutical Meningococcal Vaccine Product and Services
9.16.4 AIM Persistence Biopharmaceutical Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 AIM Persistence Biopharmaceutical Recent Developments/Updates
9.16.6 AIM Persistence Biopharmaceutical Competitive Strengths & Weaknesses
9.17 NPO Microgen
9.17.1 NPO Microgen Details
9.17.2 NPO Microgen Major Business
9.17.3 NPO Microgen Meningococcal Vaccine Product and Services
9.17.4 NPO Microgen Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 NPO Microgen Recent Developments/Updates
9.17.6 NPO Microgen Competitive Strengths & Weaknesses
9.18 Incepta Vaccine
9.18.1 Incepta Vaccine Details
9.18.2 Incepta Vaccine Major Business
9.18.3 Incepta Vaccine Meningococcal Vaccine Product and Services
9.18.4 Incepta Vaccine Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Incepta Vaccine Recent Developments/Updates
9.18.6 Incepta Vaccine Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Meningococcal Vaccine Industry Chain
10.2 Meningococcal Vaccine Upstream Analysis
10.2.1 Meningococcal Vaccine Core Raw Materials
10.2.2 Main Manufacturers of Meningococcal Vaccine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Meningococcal Vaccine Production Mode
10.6 Meningococcal Vaccine Procurement Model
10.7 Meningococcal Vaccine Industry Sales Model and Sales Channels
10.7.1 Meningococcal Vaccine Sales Model
10.7.2 Meningococcal Vaccine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Meningococcal Vaccine Introduction
1.2 World Meningococcal Vaccine Supply & Forecast
1.2.1 World Meningococcal Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Meningococcal Vaccine Production (2021-2032)
1.2.3 World Meningococcal Vaccine Pricing Trends (2021-2032)
1.3 World Meningococcal Vaccine Production by Region (Based on Production Site)
1.3.1 World Meningococcal Vaccine Production Value by Region (2021-2032)
1.3.2 World Meningococcal Vaccine Production by Region (2021-2032)
1.3.3 World Meningococcal Vaccine Average Price by Region (2021-2032)
1.3.4 North America Meningococcal Vaccine Production (2021-2032)
1.3.5 Europe Meningococcal Vaccine Production (2021-2032)
1.3.6 China Meningococcal Vaccine Production (2021-2032)
1.3.7 India Meningococcal Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Meningococcal Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Meningococcal Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Meningococcal Vaccine Demand (2021-2032)
2.2 World Meningococcal Vaccine Consumption by Region
2.2.1 World Meningococcal Vaccine Consumption by Region (2021-2026)
2.2.2 World Meningococcal Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Meningococcal Vaccine Consumption (2021-2032)
2.4 China Meningococcal Vaccine Consumption (2021-2032)
2.5 Europe Meningococcal Vaccine Consumption (2021-2032)
2.6 Japan Meningococcal Vaccine Consumption (2021-2032)
2.7 South Korea Meningococcal Vaccine Consumption (2021-2032)
2.8 ASEAN Meningococcal Vaccine Consumption (2021-2032)
2.9 India Meningococcal Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Meningococcal Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Meningococcal Vaccine Production by Manufacturer (2021-2026)
3.3 World Meningococcal Vaccine Average Price by Manufacturer (2021-2026)
3.4 Meningococcal Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Meningococcal Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Meningococcal Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Meningococcal Vaccine in 2025
3.6 Meningococcal Vaccine Market: Overall Company Footprint Analysis
3.6.1 Meningococcal Vaccine Market: Region Footprint
3.6.2 Meningococcal Vaccine Market: Company Product Type Footprint
3.6.3 Meningococcal Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Meningococcal Vaccine Production Value Comparison
4.1.1 United States VS China: Meningococcal Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Meningococcal Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Meningococcal Vaccine Production Comparison
4.2.1 United States VS China: Meningococcal Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Meningococcal Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Meningococcal Vaccine Consumption Comparison
4.3.1 United States VS China: Meningococcal Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Meningococcal Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Meningococcal Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Meningococcal Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Meningococcal Vaccine Production (2021-2026)
4.5 China Based Meningococcal Vaccine Manufacturers and Market Share
4.5.1 China Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Meningococcal Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Meningococcal Vaccine Production (2021-2026)
4.6 Rest of World Based Meningococcal Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Meningococcal Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Meningococcal Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY VACCINE PLATFORM
5.1 World Meningococcal Vaccine Market Size Overview by Vaccine Platform: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Vaccine Platform
5.2.1 Plain Polysaccharide Vaccines
5.2.2 Conjugate Vaccines
5.2.3 Recombinant Protein Vaccines
5.2.4 Multi-Platform Vaccines
5.3 Market Segment by Vaccine Platform
5.3.1 World Meningococcal Vaccine Production by Vaccine Platform (2021-2032)
5.3.2 World Meningococcal Vaccine Production Value by Vaccine Platform (2021-2032)
5.3.3 World Meningococcal Vaccine Average Price by Vaccine Platform (2021-2032)
6 MARKET ANALYSIS BY SEROGROUP COVERAGE
6.1 World Meningococcal Vaccine Market Size Overview by Serogroup Coverage: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Serogroup Coverage
6.2.1 MenA Vaccines
6.2.2 MenB Vaccines
6.2.3 MenC Vaccines
6.2.4 MenAC Vaccines
6.2.5 MenBC Vaccines
6.2.6 MenACW Vaccines
6.2.7 MenACWY Vaccines
6.2.8 MenABCWY Vaccines
6.2.9 MenACWYX Vaccines
6.3 Market Segment by Serogroup Coverage
6.3.1 World Meningococcal Vaccine Production by Serogroup Coverage (2021-2032)
6.3.2 World Meningococcal Vaccine Production Value by Serogroup Coverage (2021-2032)
6.3.3 World Meningococcal Vaccine Average Price by Serogroup Coverage (2021-2032)
7 MARKET ANALYSIS BY PRESENTATION
7.1 World Meningococcal Vaccine Market Size Overview by Presentation: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Presentation
7.2.1 Single-Dose Liquid
7.2.2 Multi-Dose Liquid
7.2.3 Single-Dose Lyophilized
7.2.4 Multi-Dose Lyophilized
7.2.5 Multi-Component Kit
7.3 Market Segment by Presentation
7.3.1 World Meningococcal Vaccine Production by Presentation (2021-2032)
7.3.2 World Meningococcal Vaccine Production Value by Presentation (2021-2032)
7.3.3 World Meningococcal Vaccine Average Price by Presentation (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Meningococcal Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Routine Pediatric Immunization
8.2.2 Routine Adolescent Immunization
8.2.3 Preventive Mass Campaigns
8.2.4 Outbreak Response
8.2.5 High-Risk Clinical Immunization
8.2.6 Travel Immunization
8.2.7 Institutional Immunization
8.2.8 Occupational Immunization
8.2.9 Catch-Up Immunization
8.3 Market Segment by Application
8.3.1 World Meningococcal Vaccine Production by Application (2021-2032)
8.3.2 World Meningococcal Vaccine Production Value by Application (2021-2032)
8.3.3 World Meningococcal Vaccine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 GSK
9.1.1 GSK Details
9.1.2 GSK Major Business
9.1.3 GSK Meningococcal Vaccine Product and Services
9.1.4 GSK Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 GSK Recent Developments/Updates
9.1.6 GSK Competitive Strengths & Weaknesses
9.2 Sanofi
9.2.1 Sanofi Details
9.2.2 Sanofi Major Business
9.2.3 Sanofi Meningococcal Vaccine Product and Services
9.2.4 Sanofi Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Sanofi Recent Developments/Updates
9.2.6 Sanofi Competitive Strengths & Weaknesses
9.3 Pfizer
9.3.1 Pfizer Details
9.3.2 Pfizer Major Business
9.3.3 Pfizer Meningococcal Vaccine Product and Services
9.3.4 Pfizer Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Pfizer Recent Developments/Updates
9.3.6 Pfizer Competitive Strengths & Weaknesses
9.4 Serum Institute of India
9.4.1 Serum Institute of India Details
9.4.2 Serum Institute of India Major Business
9.4.3 Serum Institute of India Meningococcal Vaccine Product and Services
9.4.4 Serum Institute of India Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Serum Institute of India Recent Developments/Updates
9.4.6 Serum Institute of India Competitive Strengths & Weaknesses
9.5 CanSino Biologics
9.5.1 CanSino Biologics Details
9.5.2 CanSino Biologics Major Business
9.5.3 CanSino Biologics Meningococcal Vaccine Product and Services
9.5.4 CanSino Biologics Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 CanSino Biologics Recent Developments/Updates
9.5.6 CanSino Biologics Competitive Strengths & Weaknesses
9.6 Yuxi Walvax Biotechnology
9.6.1 Yuxi Walvax Biotechnology Details
9.6.2 Yuxi Walvax Biotechnology Major Business
9.6.3 Yuxi Walvax Biotechnology Meningococcal Vaccine Product and Services
9.6.4 Yuxi Walvax Biotechnology Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Yuxi Walvax Biotechnology Recent Developments/Updates
9.6.6 Yuxi Walvax Biotechnology Competitive Strengths & Weaknesses
9.7 Beijing Zhifei Lvzhu Biopharmaceutical
9.7.1 Beijing Zhifei Lvzhu Biopharmaceutical Details
9.7.2 Beijing Zhifei Lvzhu Biopharmaceutical Major Business
9.7.3 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product and Services
9.7.4 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Beijing Zhifei Lvzhu Biopharmaceutical Recent Developments/Updates
9.7.6 Beijing Zhifei Lvzhu Biopharmaceutical Competitive Strengths & Weaknesses
9.8 China National Biotec Group
9.8.1 China National Biotec Group Details
9.8.2 China National Biotec Group Major Business
9.8.3 China National Biotec Group Meningococcal Vaccine Product and Services
9.8.4 China National Biotec Group Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 China National Biotec Group Recent Developments/Updates
9.8.6 China National Biotec Group Competitive Strengths & Weaknesses
9.9 Funda??o Oswaldo Cruz
9.9.1 Funda??o Oswaldo Cruz Details
9.9.2 Funda??o Oswaldo Cruz Major Business
9.9.3 Funda??o Oswaldo Cruz Meningococcal Vaccine Product and Services
9.9.4 Funda??o Oswaldo Cruz Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Funda??o Oswaldo Cruz Recent Developments/Updates
9.9.6 Funda??o Oswaldo Cruz Competitive Strengths & Weaknesses
9.10 Funda??o Ezequiel Dias
9.10.1 Funda??o Ezequiel Dias Details
9.10.2 Funda??o Ezequiel Dias Major Business
9.10.3 Funda??o Ezequiel Dias Meningococcal Vaccine Product and Services
9.10.4 Funda??o Ezequiel Dias Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Funda??o Ezequiel Dias Recent Developments/Updates
9.10.6 Funda??o Ezequiel Dias Competitive Strengths & Weaknesses
9.11 Instituto Finlay de Vacunas
9.11.1 Instituto Finlay de Vacunas Details
9.11.2 Instituto Finlay de Vacunas Major Business
9.11.3 Instituto Finlay de Vacunas Meningococcal Vaccine Product and Services
9.11.4 Instituto Finlay de Vacunas Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Instituto Finlay de Vacunas Recent Developments/Updates
9.11.6 Instituto Finlay de Vacunas Competitive Strengths & Weaknesses
9.12 PT Bio Farma
9.12.1 PT Bio Farma Details
9.12.2 PT Bio Farma Major Business
9.12.3 PT Bio Farma Meningococcal Vaccine Product and Services
9.12.4 PT Bio Farma Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 PT Bio Farma Recent Developments/Updates
9.12.6 PT Bio Farma Competitive Strengths & Weaknesses
9.13 Hualan Biological Bacterin
9.13.1 Hualan Biological Bacterin Details
9.13.2 Hualan Biological Bacterin Major Business
9.13.3 Hualan Biological Bacterin Meningococcal Vaccine Product and Services
9.13.4 Hualan Biological Bacterin Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Hualan Biological Bacterin Recent Developments/Updates
9.13.6 Hualan Biological Bacterin Competitive Strengths & Weaknesses
9.14 Chengdu Olymvax Biopharmaceuticals
9.14.1 Chengdu Olymvax Biopharmaceuticals Details
9.14.2 Chengdu Olymvax Biopharmaceuticals Major Business
9.14.3 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product and Services
9.14.4 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Chengdu Olymvax Biopharmaceuticals Recent Developments/Updates
9.14.6 Chengdu Olymvax Biopharmaceuticals Competitive Strengths & Weaknesses
9.15 Royal Wuxi Bio-Pharmaceutical
9.15.1 Royal Wuxi Bio-Pharmaceutical Details
9.15.2 Royal Wuxi Bio-Pharmaceutical Major Business
9.15.3 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product and Services
9.15.4 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Royal Wuxi Bio-Pharmaceutical Recent Developments/Updates
9.15.6 Royal Wuxi Bio-Pharmaceutical Competitive Strengths & Weaknesses
9.16 AIM Persistence Biopharmaceutical
9.16.1 AIM Persistence Biopharmaceutical Details
9.16.2 AIM Persistence Biopharmaceutical Major Business
9.16.3 AIM Persistence Biopharmaceutical Meningococcal Vaccine Product and Services
9.16.4 AIM Persistence Biopharmaceutical Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 AIM Persistence Biopharmaceutical Recent Developments/Updates
9.16.6 AIM Persistence Biopharmaceutical Competitive Strengths & Weaknesses
9.17 NPO Microgen
9.17.1 NPO Microgen Details
9.17.2 NPO Microgen Major Business
9.17.3 NPO Microgen Meningococcal Vaccine Product and Services
9.17.4 NPO Microgen Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 NPO Microgen Recent Developments/Updates
9.17.6 NPO Microgen Competitive Strengths & Weaknesses
9.18 Incepta Vaccine
9.18.1 Incepta Vaccine Details
9.18.2 Incepta Vaccine Major Business
9.18.3 Incepta Vaccine Meningococcal Vaccine Product and Services
9.18.4 Incepta Vaccine Meningococcal Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Incepta Vaccine Recent Developments/Updates
9.18.6 Incepta Vaccine Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Meningococcal Vaccine Industry Chain
10.2 Meningococcal Vaccine Upstream Analysis
10.2.1 Meningococcal Vaccine Core Raw Materials
10.2.2 Main Manufacturers of Meningococcal Vaccine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Meningococcal Vaccine Production Mode
10.6 Meningococcal Vaccine Procurement Model
10.7 Meningococcal Vaccine Industry Sales Model and Sales Channels
10.7.1 Meningococcal Vaccine Sales Model
10.7.2 Meningococcal Vaccine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Meningococcal Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Meningococcal Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Meningococcal Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Meningococcal Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Meningococcal Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Meningococcal Vaccine Production by Region (2021-2026) & (million Dose)
Table 7. World Meningococcal Vaccine Production by Region (2027-2032) & (million Dose)
Table 8. World Meningococcal Vaccine Production Market Share by Region (2021-2026)
Table 9. World Meningococcal Vaccine Production Market Share by Region (2027-2032)
Table 10. World Meningococcal Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Meningococcal Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Meningococcal Vaccine Major Market Trends
Table 13. World Meningococcal Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (million Dose)
Table 14. World Meningococcal Vaccine Consumption by Region (2021-2026) & (million Dose)
Table 15. World Meningococcal Vaccine Consumption Forecast by Region (2027-2032) & (million Dose)
Table 16. World Meningococcal Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Meningococcal Vaccine Producers in 2025
Table 18. World Meningococcal Vaccine Production by Manufacturer (2021-2026) & (million Dose)
Table 19. Production Market Share of Key Meningococcal Vaccine Producers in 2025
Table 20. World Meningococcal Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Meningococcal Vaccine Company Evaluation Quadrant
Table 22. World Meningococcal Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Meningococcal Vaccine Production Site of Key Manufacturer
Table 24. Meningococcal Vaccine Market: Company Product Type Footprint
Table 25. Meningococcal Vaccine Market: Company Product Application Footprint
Table 26. Meningococcal Vaccine Competitive Factors
Table 27. Meningococcal Vaccine New Entrant and Capacity Expansion Plans
Table 28. Meningococcal Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Meningococcal Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Meningococcal Vaccine Production Comparison, (2021 & 2025 & 2032) & (million Dose)
Table 31. United States VS China Meningococcal Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (million Dose)
Table 32. United States Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Meningococcal Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Meningococcal Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Meningococcal Vaccine Production (2021-2026) & (million Dose)
Table 36. United States Based Manufacturers Meningococcal Vaccine Production Market Share (2021-2026)
Table 37. China Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Meningococcal Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Meningococcal Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Meningococcal Vaccine Production, (2021-2026) & (million Dose)
Table 41. China Based Manufacturers Meningococcal Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Meningococcal Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Meningococcal Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Meningococcal Vaccine Production, (2021-2026) & (million Dose)
Table 46. Rest of World Based Manufacturers Meningococcal Vaccine Production Market Share (2021-2026)
Table 47. World Meningococcal Vaccine Production Value by Vaccine Platform, (USD Million), 2021 & 2025 & 2032
Table 48. World Meningococcal Vaccine Production by Vaccine Platform (2021-2026) & (million Dose)
Table 49. World Meningococcal Vaccine Production by Vaccine Platform (2027-2032) & (million Dose)
Table 50. World Meningococcal Vaccine Production Value by Vaccine Platform (2021-2026) & (USD Million)
Table 51. World Meningococcal Vaccine Production Value by Vaccine Platform (2027-2032) & (USD Million)
Table 52. World Meningococcal Vaccine Average Price by Vaccine Platform (2021-2026) & (US$/Dose)
Table 53. World Meningococcal Vaccine Average Price by Vaccine Platform (2027-2032) & (US$/Dose)
Table 54. World Meningococcal Vaccine Production Value by Serogroup Coverage, (USD Million), 2021 & 2025 & 2032
Table 55. World Meningococcal Vaccine Production by Serogroup Coverage (2021-2026) & (million Dose)
Table 56. World Meningococcal Vaccine Production by Serogroup Coverage (2027-2032) & (million Dose)
Table 57. World Meningococcal Vaccine Production Value by Serogroup Coverage (2021-2026) & (USD Million)
Table 58. World Meningococcal Vaccine Production Value by Serogroup Coverage (2027-2032) & (USD Million)
Table 59. World Meningococcal Vaccine Average Price by Serogroup Coverage (2021-2026) & (US$/Dose)
Table 60. World Meningococcal Vaccine Average Price by Serogroup Coverage (2027-2032) & (US$/Dose)
Table 61. World Meningococcal Vaccine Production Value by Presentation, (USD Million), 2021 & 2025 & 2032
Table 62. World Meningococcal Vaccine Production by Presentation (2021-2026) & (million Dose)
Table 63. World Meningococcal Vaccine Production by Presentation (2027-2032) & (million Dose)
Table 64. World Meningococcal Vaccine Production Value by Presentation (2021-2026) & (USD Million)
Table 65. World Meningococcal Vaccine Production Value by Presentation (2027-2032) & (USD Million)
Table 66. World Meningococcal Vaccine Average Price by Presentation (2021-2026) & (US$/Dose)
Table 67. World Meningococcal Vaccine Average Price by Presentation (2027-2032) & (US$/Dose)
Table 68. World Meningococcal Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Meningococcal Vaccine Production by Application (2021-2026) & (million Dose)
Table 70. World Meningococcal Vaccine Production by Application (2027-2032) & (million Dose)
Table 71. World Meningococcal Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Meningococcal Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Meningococcal Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Meningococcal Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. GSK Basic Information, Manufacturing Base and Competitors
Table 76. GSK Major Business
Table 77. GSK Meningococcal Vaccine Product and Services
Table 78. GSK Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. GSK Recent Developments/Updates
Table 80. GSK Competitive Strengths & Weaknesses
Table 81. Sanofi Basic Information, Manufacturing Base and Competitors
Table 82. Sanofi Major Business
Table 83. Sanofi Meningococcal Vaccine Product and Services
Table 84. Sanofi Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Sanofi Recent Developments/Updates
Table 86. Sanofi Competitive Strengths & Weaknesses
Table 87. Pfizer Basic Information, Manufacturing Base and Competitors
Table 88. Pfizer Major Business
Table 89. Pfizer Meningococcal Vaccine Product and Services
Table 90. Pfizer Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Pfizer Recent Developments/Updates
Table 92. Pfizer Competitive Strengths & Weaknesses
Table 93. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 94. Serum Institute of India Major Business
Table 95. Serum Institute of India Meningococcal Vaccine Product and Services
Table 96. Serum Institute of India Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Serum Institute of India Recent Developments/Updates
Table 98. Serum Institute of India Competitive Strengths & Weaknesses
Table 99. CanSino Biologics Basic Information, Manufacturing Base and Competitors
Table 100. CanSino Biologics Major Business
Table 101. CanSino Biologics Meningococcal Vaccine Product and Services
Table 102. CanSino Biologics Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. CanSino Biologics Recent Developments/Updates
Table 104. CanSino Biologics Competitive Strengths & Weaknesses
Table 105. Yuxi Walvax Biotechnology Basic Information, Manufacturing Base and Competitors
Table 106. Yuxi Walvax Biotechnology Major Business
Table 107. Yuxi Walvax Biotechnology Meningococcal Vaccine Product and Services
Table 108. Yuxi Walvax Biotechnology Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Yuxi Walvax Biotechnology Recent Developments/Updates
Table 110. Yuxi Walvax Biotechnology Competitive Strengths & Weaknesses
Table 111. Beijing Zhifei Lvzhu Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Beijing Zhifei Lvzhu Biopharmaceutical Major Business
Table 113. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product and Services
Table 114. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Beijing Zhifei Lvzhu Biopharmaceutical Recent Developments/Updates
Table 116. Beijing Zhifei Lvzhu Biopharmaceutical Competitive Strengths & Weaknesses
Table 117. China National Biotec Group Basic Information, Manufacturing Base and Competitors
Table 118. China National Biotec Group Major Business
Table 119. China National Biotec Group Meningococcal Vaccine Product and Services
Table 120. China National Biotec Group Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. China National Biotec Group Recent Developments/Updates
Table 122. China National Biotec Group Competitive Strengths & Weaknesses
Table 123. Funda??o Oswaldo Cruz Basic Information, Manufacturing Base and Competitors
Table 124. Funda??o Oswaldo Cruz Major Business
Table 125. Funda??o Oswaldo Cruz Meningococcal Vaccine Product and Services
Table 126. Funda??o Oswaldo Cruz Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Funda??o Oswaldo Cruz Recent Developments/Updates
Table 128. Funda??o Oswaldo Cruz Competitive Strengths & Weaknesses
Table 129. Funda??o Ezequiel Dias Basic Information, Manufacturing Base and Competitors
Table 130. Funda??o Ezequiel Dias Major Business
Table 131. Funda??o Ezequiel Dias Meningococcal Vaccine Product and Services
Table 132. Funda??o Ezequiel Dias Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Funda??o Ezequiel Dias Recent Developments/Updates
Table 134. Funda??o Ezequiel Dias Competitive Strengths & Weaknesses
Table 135. Instituto Finlay de Vacunas Basic Information, Manufacturing Base and Competitors
Table 136. Instituto Finlay de Vacunas Major Business
Table 137. Instituto Finlay de Vacunas Meningococcal Vaccine Product and Services
Table 138. Instituto Finlay de Vacunas Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Instituto Finlay de Vacunas Recent Developments/Updates
Table 140. Instituto Finlay de Vacunas Competitive Strengths & Weaknesses
Table 141. PT Bio Farma Basic Information, Manufacturing Base and Competitors
Table 142. PT Bio Farma Major Business
Table 143. PT Bio Farma Meningococcal Vaccine Product and Services
Table 144. PT Bio Farma Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. PT Bio Farma Recent Developments/Updates
Table 146. PT Bio Farma Competitive Strengths & Weaknesses
Table 147. Hualan Biological Bacterin Basic Information, Manufacturing Base and Competitors
Table 148. Hualan Biological Bacterin Major Business
Table 149. Hualan Biological Bacterin Meningococcal Vaccine Product and Services
Table 150. Hualan Biological Bacterin Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Hualan Biological Bacterin Recent Developments/Updates
Table 152. Hualan Biological Bacterin Competitive Strengths & Weaknesses
Table 153. Chengdu Olymvax Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 154. Chengdu Olymvax Biopharmaceuticals Major Business
Table 155. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product and Services
Table 156. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Chengdu Olymvax Biopharmaceuticals Recent Developments/Updates
Table 158. Chengdu Olymvax Biopharmaceuticals Competitive Strengths & Weaknesses
Table 159. Royal Wuxi Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 160. Royal Wuxi Bio-Pharmaceutical Major Business
Table 161. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product and Services
Table 162. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Royal Wuxi Bio-Pharmaceutical Recent Developments/Updates
Table 164. Royal Wuxi Bio-Pharmaceutical Competitive Strengths & Weaknesses
Table 165. AIM Persistence Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 166. AIM Persistence Biopharmaceutical Major Business
Table 167. AIM Persistence Biopharmaceutical Meningococcal Vaccine Product and Services
Table 168. AIM Persistence Biopharmaceutical Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. AIM Persistence Biopharmaceutical Recent Developments/Updates
Table 170. AIM Persistence Biopharmaceutical Competitive Strengths & Weaknesses
Table 171. NPO Microgen Basic Information, Manufacturing Base and Competitors
Table 172. NPO Microgen Major Business
Table 173. NPO Microgen Meningococcal Vaccine Product and Services
Table 174. NPO Microgen Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. NPO Microgen Recent Developments/Updates
Table 176. NPO Microgen Competitive Strengths & Weaknesses
Table 177. Incepta Vaccine Basic Information, Manufacturing Base and Competitors
Table 178. Incepta Vaccine Major Business
Table 179. Incepta Vaccine Meningococcal Vaccine Product and Services
Table 180. Incepta Vaccine Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Incepta Vaccine Recent Developments/Updates
Table 182. Incepta Vaccine Competitive Strengths & Weaknesses
Table 183. Global Key Players of Meningococcal Vaccine Upstream (Raw Materials)
Table 184. Global Meningococcal Vaccine Typical Customers
Table 185. Meningococcal Vaccine Typical Distributors
Table 1. World Meningococcal Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Meningococcal Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Meningococcal Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Meningococcal Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Meningococcal Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Meningococcal Vaccine Production by Region (2021-2026) & (million Dose)
Table 7. World Meningococcal Vaccine Production by Region (2027-2032) & (million Dose)
Table 8. World Meningococcal Vaccine Production Market Share by Region (2021-2026)
Table 9. World Meningococcal Vaccine Production Market Share by Region (2027-2032)
Table 10. World Meningococcal Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Meningococcal Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Meningococcal Vaccine Major Market Trends
Table 13. World Meningococcal Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (million Dose)
Table 14. World Meningococcal Vaccine Consumption by Region (2021-2026) & (million Dose)
Table 15. World Meningococcal Vaccine Consumption Forecast by Region (2027-2032) & (million Dose)
Table 16. World Meningococcal Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Meningococcal Vaccine Producers in 2025
Table 18. World Meningococcal Vaccine Production by Manufacturer (2021-2026) & (million Dose)
Table 19. Production Market Share of Key Meningococcal Vaccine Producers in 2025
Table 20. World Meningococcal Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Meningococcal Vaccine Company Evaluation Quadrant
Table 22. World Meningococcal Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Meningococcal Vaccine Production Site of Key Manufacturer
Table 24. Meningococcal Vaccine Market: Company Product Type Footprint
Table 25. Meningococcal Vaccine Market: Company Product Application Footprint
Table 26. Meningococcal Vaccine Competitive Factors
Table 27. Meningococcal Vaccine New Entrant and Capacity Expansion Plans
Table 28. Meningococcal Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Meningococcal Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Meningococcal Vaccine Production Comparison, (2021 & 2025 & 2032) & (million Dose)
Table 31. United States VS China Meningococcal Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (million Dose)
Table 32. United States Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Meningococcal Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Meningococcal Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Meningococcal Vaccine Production (2021-2026) & (million Dose)
Table 36. United States Based Manufacturers Meningococcal Vaccine Production Market Share (2021-2026)
Table 37. China Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Meningococcal Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Meningococcal Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Meningococcal Vaccine Production, (2021-2026) & (million Dose)
Table 41. China Based Manufacturers Meningococcal Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Meningococcal Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Meningococcal Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Meningococcal Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Meningococcal Vaccine Production, (2021-2026) & (million Dose)
Table 46. Rest of World Based Manufacturers Meningococcal Vaccine Production Market Share (2021-2026)
Table 47. World Meningococcal Vaccine Production Value by Vaccine Platform, (USD Million), 2021 & 2025 & 2032
Table 48. World Meningococcal Vaccine Production by Vaccine Platform (2021-2026) & (million Dose)
Table 49. World Meningococcal Vaccine Production by Vaccine Platform (2027-2032) & (million Dose)
Table 50. World Meningococcal Vaccine Production Value by Vaccine Platform (2021-2026) & (USD Million)
Table 51. World Meningococcal Vaccine Production Value by Vaccine Platform (2027-2032) & (USD Million)
Table 52. World Meningococcal Vaccine Average Price by Vaccine Platform (2021-2026) & (US$/Dose)
Table 53. World Meningococcal Vaccine Average Price by Vaccine Platform (2027-2032) & (US$/Dose)
Table 54. World Meningococcal Vaccine Production Value by Serogroup Coverage, (USD Million), 2021 & 2025 & 2032
Table 55. World Meningococcal Vaccine Production by Serogroup Coverage (2021-2026) & (million Dose)
Table 56. World Meningococcal Vaccine Production by Serogroup Coverage (2027-2032) & (million Dose)
Table 57. World Meningococcal Vaccine Production Value by Serogroup Coverage (2021-2026) & (USD Million)
Table 58. World Meningococcal Vaccine Production Value by Serogroup Coverage (2027-2032) & (USD Million)
Table 59. World Meningococcal Vaccine Average Price by Serogroup Coverage (2021-2026) & (US$/Dose)
Table 60. World Meningococcal Vaccine Average Price by Serogroup Coverage (2027-2032) & (US$/Dose)
Table 61. World Meningococcal Vaccine Production Value by Presentation, (USD Million), 2021 & 2025 & 2032
Table 62. World Meningococcal Vaccine Production by Presentation (2021-2026) & (million Dose)
Table 63. World Meningococcal Vaccine Production by Presentation (2027-2032) & (million Dose)
Table 64. World Meningococcal Vaccine Production Value by Presentation (2021-2026) & (USD Million)
Table 65. World Meningococcal Vaccine Production Value by Presentation (2027-2032) & (USD Million)
Table 66. World Meningococcal Vaccine Average Price by Presentation (2021-2026) & (US$/Dose)
Table 67. World Meningococcal Vaccine Average Price by Presentation (2027-2032) & (US$/Dose)
Table 68. World Meningococcal Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Meningococcal Vaccine Production by Application (2021-2026) & (million Dose)
Table 70. World Meningococcal Vaccine Production by Application (2027-2032) & (million Dose)
Table 71. World Meningococcal Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Meningococcal Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Meningococcal Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Meningococcal Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. GSK Basic Information, Manufacturing Base and Competitors
Table 76. GSK Major Business
Table 77. GSK Meningococcal Vaccine Product and Services
Table 78. GSK Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. GSK Recent Developments/Updates
Table 80. GSK Competitive Strengths & Weaknesses
Table 81. Sanofi Basic Information, Manufacturing Base and Competitors
Table 82. Sanofi Major Business
Table 83. Sanofi Meningococcal Vaccine Product and Services
Table 84. Sanofi Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Sanofi Recent Developments/Updates
Table 86. Sanofi Competitive Strengths & Weaknesses
Table 87. Pfizer Basic Information, Manufacturing Base and Competitors
Table 88. Pfizer Major Business
Table 89. Pfizer Meningococcal Vaccine Product and Services
Table 90. Pfizer Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Pfizer Recent Developments/Updates
Table 92. Pfizer Competitive Strengths & Weaknesses
Table 93. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 94. Serum Institute of India Major Business
Table 95. Serum Institute of India Meningococcal Vaccine Product and Services
Table 96. Serum Institute of India Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Serum Institute of India Recent Developments/Updates
Table 98. Serum Institute of India Competitive Strengths & Weaknesses
Table 99. CanSino Biologics Basic Information, Manufacturing Base and Competitors
Table 100. CanSino Biologics Major Business
Table 101. CanSino Biologics Meningococcal Vaccine Product and Services
Table 102. CanSino Biologics Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. CanSino Biologics Recent Developments/Updates
Table 104. CanSino Biologics Competitive Strengths & Weaknesses
Table 105. Yuxi Walvax Biotechnology Basic Information, Manufacturing Base and Competitors
Table 106. Yuxi Walvax Biotechnology Major Business
Table 107. Yuxi Walvax Biotechnology Meningococcal Vaccine Product and Services
Table 108. Yuxi Walvax Biotechnology Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Yuxi Walvax Biotechnology Recent Developments/Updates
Table 110. Yuxi Walvax Biotechnology Competitive Strengths & Weaknesses
Table 111. Beijing Zhifei Lvzhu Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Beijing Zhifei Lvzhu Biopharmaceutical Major Business
Table 113. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product and Services
Table 114. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Beijing Zhifei Lvzhu Biopharmaceutical Recent Developments/Updates
Table 116. Beijing Zhifei Lvzhu Biopharmaceutical Competitive Strengths & Weaknesses
Table 117. China National Biotec Group Basic Information, Manufacturing Base and Competitors
Table 118. China National Biotec Group Major Business
Table 119. China National Biotec Group Meningococcal Vaccine Product and Services
Table 120. China National Biotec Group Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. China National Biotec Group Recent Developments/Updates
Table 122. China National Biotec Group Competitive Strengths & Weaknesses
Table 123. Funda??o Oswaldo Cruz Basic Information, Manufacturing Base and Competitors
Table 124. Funda??o Oswaldo Cruz Major Business
Table 125. Funda??o Oswaldo Cruz Meningococcal Vaccine Product and Services
Table 126. Funda??o Oswaldo Cruz Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Funda??o Oswaldo Cruz Recent Developments/Updates
Table 128. Funda??o Oswaldo Cruz Competitive Strengths & Weaknesses
Table 129. Funda??o Ezequiel Dias Basic Information, Manufacturing Base and Competitors
Table 130. Funda??o Ezequiel Dias Major Business
Table 131. Funda??o Ezequiel Dias Meningococcal Vaccine Product and Services
Table 132. Funda??o Ezequiel Dias Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Funda??o Ezequiel Dias Recent Developments/Updates
Table 134. Funda??o Ezequiel Dias Competitive Strengths & Weaknesses
Table 135. Instituto Finlay de Vacunas Basic Information, Manufacturing Base and Competitors
Table 136. Instituto Finlay de Vacunas Major Business
Table 137. Instituto Finlay de Vacunas Meningococcal Vaccine Product and Services
Table 138. Instituto Finlay de Vacunas Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Instituto Finlay de Vacunas Recent Developments/Updates
Table 140. Instituto Finlay de Vacunas Competitive Strengths & Weaknesses
Table 141. PT Bio Farma Basic Information, Manufacturing Base and Competitors
Table 142. PT Bio Farma Major Business
Table 143. PT Bio Farma Meningococcal Vaccine Product and Services
Table 144. PT Bio Farma Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. PT Bio Farma Recent Developments/Updates
Table 146. PT Bio Farma Competitive Strengths & Weaknesses
Table 147. Hualan Biological Bacterin Basic Information, Manufacturing Base and Competitors
Table 148. Hualan Biological Bacterin Major Business
Table 149. Hualan Biological Bacterin Meningococcal Vaccine Product and Services
Table 150. Hualan Biological Bacterin Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Hualan Biological Bacterin Recent Developments/Updates
Table 152. Hualan Biological Bacterin Competitive Strengths & Weaknesses
Table 153. Chengdu Olymvax Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 154. Chengdu Olymvax Biopharmaceuticals Major Business
Table 155. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product and Services
Table 156. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Chengdu Olymvax Biopharmaceuticals Recent Developments/Updates
Table 158. Chengdu Olymvax Biopharmaceuticals Competitive Strengths & Weaknesses
Table 159. Royal Wuxi Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 160. Royal Wuxi Bio-Pharmaceutical Major Business
Table 161. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product and Services
Table 162. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Royal Wuxi Bio-Pharmaceutical Recent Developments/Updates
Table 164. Royal Wuxi Bio-Pharmaceutical Competitive Strengths & Weaknesses
Table 165. AIM Persistence Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 166. AIM Persistence Biopharmaceutical Major Business
Table 167. AIM Persistence Biopharmaceutical Meningococcal Vaccine Product and Services
Table 168. AIM Persistence Biopharmaceutical Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. AIM Persistence Biopharmaceutical Recent Developments/Updates
Table 170. AIM Persistence Biopharmaceutical Competitive Strengths & Weaknesses
Table 171. NPO Microgen Basic Information, Manufacturing Base and Competitors
Table 172. NPO Microgen Major Business
Table 173. NPO Microgen Meningococcal Vaccine Product and Services
Table 174. NPO Microgen Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. NPO Microgen Recent Developments/Updates
Table 176. NPO Microgen Competitive Strengths & Weaknesses
Table 177. Incepta Vaccine Basic Information, Manufacturing Base and Competitors
Table 178. Incepta Vaccine Major Business
Table 179. Incepta Vaccine Meningococcal Vaccine Product and Services
Table 180. Incepta Vaccine Meningococcal Vaccine Production (million Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Incepta Vaccine Recent Developments/Updates
Table 182. Incepta Vaccine Competitive Strengths & Weaknesses
Table 183. Global Key Players of Meningococcal Vaccine Upstream (Raw Materials)
Table 184. Global Meningococcal Vaccine Typical Customers
Table 185. Meningococcal Vaccine Typical Distributors
LIST OF FIGURES
Figure 1. Meningococcal Vaccine Picture
Figure 2. World Meningococcal Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Meningococcal Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 5. World Meningococcal Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Meningococcal Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Meningococcal Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 9. Europe Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 10. China Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 11. India Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 12. Meningococcal Vaccine Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 15. World Meningococcal Vaccine Consumption Market Share by Region (2021-2032)
Figure 16. United States Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 17. China Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 18. Europe Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 19. Japan Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 20. South Korea Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 21. ASEAN Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 22. India Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 23. Producer Shipments of Meningococcal Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Meningococcal Vaccine Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Meningococcal Vaccine Markets in 2025
Figure 26. United States VS China: Meningococcal Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Meningococcal Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Meningococcal Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Meningococcal Vaccine Production Market Share 2025
Figure 30. China Based Manufacturers Meningococcal Vaccine Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Meningococcal Vaccine Production Market Share 2025
Figure 32. World Meningococcal Vaccine Production Value by Vaccine Platform, (USD Million), 2021 & 2025 & 2032
Figure 33. World Meningococcal Vaccine Production Value Market Share by Vaccine Platform in 2025
Figure 34. Plain Polysaccharide Vaccines
Figure 35. Conjugate Vaccines
Figure 36. Recombinant Protein Vaccines
Figure 37. Multi-Platform Vaccines
Figure 38. World Meningococcal Vaccine Production Market Share by Vaccine Platform (2021-2032)
Figure 39. World Meningococcal Vaccine Production Value Market Share by Vaccine Platform (2021-2032)
Figure 40. World Meningococcal Vaccine Average Price by Vaccine Platform (2021-2032) & (US$/Dose)
Figure 41. World Meningococcal Vaccine Production Value by Serogroup Coverage, (USD Million), 2021 & 2025 & 2032
Figure 42. World Meningococcal Vaccine Production Value Market Share by Serogroup Coverage in 2025
Figure 43. MenA Vaccines
Figure 44. MenB Vaccines
Figure 45. MenC Vaccines
Figure 46. MenAC Vaccines
Figure 47. MenBC Vaccines
Figure 48. MenACW Vaccines
Figure 49. MenACWY Vaccines
Figure 50. MenABCWY Vaccines
Figure 51. MenACWY Vaccines
Figure 52. World Meningococcal Vaccine Production Market Share by Serogroup Coverage (2021-2032)
Figure 53. World Meningococcal Vaccine Production Value Market Share by Serogroup Coverage (2021-2032)
Figure 54. World Meningococcal Vaccine Average Price by Serogroup Coverage (2021-2032) & (US$/Dose)
Figure 55. World Meningococcal Vaccine Production Value by Presentation, (USD Million), 2021 & 2025 & 2032
Figure 56. World Meningococcal Vaccine Production Value Market Share by Presentation in 2025
Figure 57. Single-Dose Liquid
Figure 58. Multi-Dose Liquid
Figure 59. Single-Dose Lyophilized
Figure 60. Multi-Dose Lyophilized
Figure 61. Multi-Component Kit
Figure 62. World Meningococcal Vaccine Production Market Share by Presentation (2021-2032)
Figure 63. World Meningococcal Vaccine Production Value Market Share by Presentation (2021-2032)
Figure 64. World Meningococcal Vaccine Average Price by Presentation (2021-2032) & (US$/Dose)
Figure 65. World Meningococcal Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 66. World Meningococcal Vaccine Production Value Market Share by Application in 2025
Figure 67. Routine Pediatric Immunization
Figure 68. Routine Adolescent Immunization
Figure 69. Preventive Mass Campaigns
Figure 70. Outbreak Response
Figure 71. High-Risk Clinical Immunization
Figure 72. Travel Immunization
Figure 73. Institutional Immunization
Figure 74. Occupational Immunization
Figure 75. Occupational Immunization
Figure 76. World Meningococcal Vaccine Production Market Share by Application (2021-2032)
Figure 77. World Meningococcal Vaccine Production Value Market Share by Application (2021-2032)
Figure 78. World Meningococcal Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 79. Meningococcal Vaccine Industry Chain
Figure 80. Meningococcal Vaccine Procurement Model
Figure 81. Meningococcal Vaccine Sales Model
Figure 82. Meningococcal Vaccine Sales Channels, Direct Sales, and Distribution
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. Meningococcal Vaccine Picture
Figure 2. World Meningococcal Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Meningococcal Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 5. World Meningococcal Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Meningococcal Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Meningococcal Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 9. Europe Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 10. China Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 11. India Meningococcal Vaccine Production (2021-2032) & (million Dose)
Figure 12. Meningococcal Vaccine Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 15. World Meningococcal Vaccine Consumption Market Share by Region (2021-2032)
Figure 16. United States Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 17. China Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 18. Europe Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 19. Japan Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 20. South Korea Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 21. ASEAN Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 22. India Meningococcal Vaccine Consumption (2021-2032) & (million Dose)
Figure 23. Producer Shipments of Meningococcal Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Meningococcal Vaccine Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Meningococcal Vaccine Markets in 2025
Figure 26. United States VS China: Meningococcal Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Meningococcal Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Meningococcal Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Meningococcal Vaccine Production Market Share 2025
Figure 30. China Based Manufacturers Meningococcal Vaccine Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Meningococcal Vaccine Production Market Share 2025
Figure 32. World Meningococcal Vaccine Production Value by Vaccine Platform, (USD Million), 2021 & 2025 & 2032
Figure 33. World Meningococcal Vaccine Production Value Market Share by Vaccine Platform in 2025
Figure 34. Plain Polysaccharide Vaccines
Figure 35. Conjugate Vaccines
Figure 36. Recombinant Protein Vaccines
Figure 37. Multi-Platform Vaccines
Figure 38. World Meningococcal Vaccine Production Market Share by Vaccine Platform (2021-2032)
Figure 39. World Meningococcal Vaccine Production Value Market Share by Vaccine Platform (2021-2032)
Figure 40. World Meningococcal Vaccine Average Price by Vaccine Platform (2021-2032) & (US$/Dose)
Figure 41. World Meningococcal Vaccine Production Value by Serogroup Coverage, (USD Million), 2021 & 2025 & 2032
Figure 42. World Meningococcal Vaccine Production Value Market Share by Serogroup Coverage in 2025
Figure 43. MenA Vaccines
Figure 44. MenB Vaccines
Figure 45. MenC Vaccines
Figure 46. MenAC Vaccines
Figure 47. MenBC Vaccines
Figure 48. MenACW Vaccines
Figure 49. MenACWY Vaccines
Figure 50. MenABCWY Vaccines
Figure 51. MenACWY Vaccines
Figure 52. World Meningococcal Vaccine Production Market Share by Serogroup Coverage (2021-2032)
Figure 53. World Meningococcal Vaccine Production Value Market Share by Serogroup Coverage (2021-2032)
Figure 54. World Meningococcal Vaccine Average Price by Serogroup Coverage (2021-2032) & (US$/Dose)
Figure 55. World Meningococcal Vaccine Production Value by Presentation, (USD Million), 2021 & 2025 & 2032
Figure 56. World Meningococcal Vaccine Production Value Market Share by Presentation in 2025
Figure 57. Single-Dose Liquid
Figure 58. Multi-Dose Liquid
Figure 59. Single-Dose Lyophilized
Figure 60. Multi-Dose Lyophilized
Figure 61. Multi-Component Kit
Figure 62. World Meningococcal Vaccine Production Market Share by Presentation (2021-2032)
Figure 63. World Meningococcal Vaccine Production Value Market Share by Presentation (2021-2032)
Figure 64. World Meningococcal Vaccine Average Price by Presentation (2021-2032) & (US$/Dose)
Figure 65. World Meningococcal Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 66. World Meningococcal Vaccine Production Value Market Share by Application in 2025
Figure 67. Routine Pediatric Immunization
Figure 68. Routine Adolescent Immunization
Figure 69. Preventive Mass Campaigns
Figure 70. Outbreak Response
Figure 71. High-Risk Clinical Immunization
Figure 72. Travel Immunization
Figure 73. Institutional Immunization
Figure 74. Occupational Immunization
Figure 75. Occupational Immunization
Figure 76. World Meningococcal Vaccine Production Market Share by Application (2021-2032)
Figure 77. World Meningococcal Vaccine Production Value Market Share by Application (2021-2032)
Figure 78. World Meningococcal Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 79. Meningococcal Vaccine Industry Chain
Figure 80. Meningococcal Vaccine Procurement Model
Figure 81. Meningococcal Vaccine Sales Model
Figure 82. Meningococcal Vaccine Sales Channels, Direct Sales, and Distribution
Figure 83. Methodology
Figure 84. Research Process and Data Source
